PARP1 and non-small cell lung carcinoma: In the Phase 1/2 ATF-07 trial (NCT02412371), the PARP inhibitor veliparib (ABT-888), when combined with concurrent chemoradiotherapy, induced DNA damage in patients with stage III NSCLC.